Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Crucell signs license deal with Taiwan firm
AbGenomics Corporation intends to use the PER.C6 cell line for its research, development and early clinical studies of monoclonal antibodies. “The unique characteristics of the PER.C6 technology as
AbGenomics Corporation intends to use the PER.C6 cell line for its research, development and early clinical studies of monoclonal antibodies. “The unique characteristics of the PER.C6 technology as
The transaction is expected to close within the next two weeks. At closing, $7.5 million in cash and $4.375 million in LAB shares will be paid. The sellers
The trial is designed to monitor the safety and tolerability of PBI-1402 and whether it has additive effects when combined with the current drug for anemia, erythropoietin (EPO)
The construction has been halted because the company expects to be able to meet the growth in insulin demand with already existing manufacturing sites and new insulin capacity
The close follows the early termination by the US Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Act. Pradefovir is an experimental hepatitis B drug,
Entelos is providing biosimulation services to J&J, compensated in part through the grant of this option, and will develop a new PhysioLab platform to support its internal development
Astellas predecessor, Fujisawa Healthcare and Daiichi Asubio Pharma's predecessor, Daiichi Suntory Pharma executed the license agreement in May, 2003. Astellas had conducted some clinical trials using carperitide in
Specifically, the research examined the co-administration of MCT-465, a toll-like receptor (TLR) agonist and IgNP, the company's antigen presenting immunoglobulin therapeutic. It found that the combination therapy not
The agreement includes annual license fees and milestone payments which could total approximately $38 million paid to Neuralstem for each licensed product. The license covers a library of
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently in phase III development. The companies plan to file for US regulatory approval of saxagliptin during the first half of